Editorial Board Members' Collection Series: Antibiotic Resistance Mechanisms and Molecular Epidemiology of ESKAPEE

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Mechanism and Evolution of Antibiotic Resistance".

Deadline for manuscript submissions: closed (30 June 2024) | Viewed by 1554

Special Issue Editor


E-Mail Website
Guest Editor
Laboratory for Process Engineering, Environment, Biotechnology and Energy (LEPABE), Department of Chemical Engineering, Faculty of Engineering, University of Porto, 4099-002 Porto, Portugal
Interests: bacterial infection; multidrug-resistance; biofilms; phytochemicals; strategies of biofilm prevention and control; quorum-sensing; quorum-quenching; virulence attenuators; drug-repurposing; molecular docking
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In an era of rapidly evolving medical science and advanced healthcare, the emergence and spread of antibiotic resistance pose a significant threat to global public health. Some of the most notorious pathogens contributing to this crisis are ESKAPEE pathogens, which include Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species, and Escherichia coli. These bacteria have a remarkable ability to "escape" the effects of antibiotics and are the leading cause of severe life-threatening hospital/community-acquired infections that are often difficult to treat. The nature to develop multi-drug resistance and the ability to acquire genes that encode resistance, combined with the propensity to form complex microbial communities named biofilms, make ESKAPEE pathogens even more recalcitrant to treatments and host immune defenses. Understanding the molecular mechanisms that underly antibiotic resistance in ESKAPEE pathogens, at both the planktonic and sessile state, is crucial for developing effective therapeutic strategies and preventing the further spread of resistance, as well as to guide antibiotic treatment decisions. The aim of the Editorial Board Members’ Collection, “Antibiotic Resistance Mechanisms and Molecular Epidemiology of ESKAPEE”, is dedicated to collecting papers that expore the genetic and molecular factors that enable ESKAPEE pathogens to resist antibiotics and the epidemiology of their transmission. We also welcome cutting-edge research and innovative approaches centered around the ongoing battle against antibiotic resistance and biofilm-associated chronic infections in ESKAPEE bacteria.

Dr. Anabela Borges
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ESKAPEE
  • ESKAPE
  • antibiotic resistance
  • antibiotic resistance mechanisms
  • molecular epidemiology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 489 KiB  
Article
Detection of KPC-216, a Novel KPC-3 Variant, in a Clinical Isolate of Klebsiella pneumoniae ST101 Co-Resistant to Ceftazidime-Avibactam and Cefiderocol
by Maria Giufrè, Giulia Errico, Maria Del Grosso, Michela Pagnotta, Bernardetta Palazzotti, Milva Ballardini, Annalisa Pantosti, Marcello Meledandri and Monica Monaco
Antibiotics 2024, 13(6), 507; https://doi.org/10.3390/antibiotics13060507 - 29 May 2024
Viewed by 1254
Abstract
Background: Carbapenemase-producing Klebsiella pneumoniae (CP-KP) represents a global threat to public health, with limited antimicrobial therapeutic options. In this study, we analyzed a ceftazidime/avibactam (CAZ-AVI)-resistant K. pneumoniae isolate obtained from a patient previously exposed to CAZ-AVI expressing a novel K. pneumoniae carbapenemase (KPC)-3 [...] Read more.
Background: Carbapenemase-producing Klebsiella pneumoniae (CP-KP) represents a global threat to public health, with limited antimicrobial therapeutic options. In this study, we analyzed a ceftazidime/avibactam (CAZ-AVI)-resistant K. pneumoniae isolate obtained from a patient previously exposed to CAZ-AVI expressing a novel K. pneumoniae carbapenemase (KPC)-3 variant. Methods: Antimicrobial susceptibility testing was performed using reference broth microdilution. Whole-genome sequencing (WGS) was performed using Illumina and Nanopore Technologies. Short- and long-reads were combined with Unicycler. Assemblies were investigated for multilocus sequence typing (MLST), antimicrobial resistance genes, porins, and plasmids. Results: The K. pneumoniae isolate (KP_RM_1) was resistant to CAZ-AVI, expanded-spectrum cephalosporins, amikacin, ertapenem, and cefiderocol (FDC) but was susceptible to tigecycline, colistin, trimethoprim/sulfamethoxazole, meropenem–vaborbactam, and imipenem–relebactam. WGS revealed that the KP_RM_1 genome is composed of a single chromosome of 5 Mbp and five circular plasmids. Further analysis showed the presence of novel blaKPC-216 located on a 72 kb plasmid. KPC-216 differs from KPC-3 by a Lysin (K) insertion at position 168 (+K168). Conclusions: We report the identification of a new KPC-3 variant associated with CAZ-AVI resistance. The KPC variants associated with CAZ-AVI resistance should be determined to promptly inform clinicians and start the appropriate antimicrobial therapy. Full article
Show Figures

Figure 1

Back to TopTop